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Abstract
Objective: Limb girdle muscular dystrophy type R9 (LGMD R9) is an autoso-
mal recessive muscle disease for which there is currently no causative treatment.
The development of putative therapies requires sensitive outcome measures for
clinical trials in this slowly progressing condition. This study extends functional
assessments and MRI muscle fat fraction measurements in an LGMD R9 cohort
across 6 years. Methods: Twenty-three participants with LGMD R9, previously
assessed over a 1-year period, were re-enrolled at 6 years. Standardized func-
tional assessments were performed including: myometry, timed tests, and
spirometry testing. Quantitative MRI was used to measure fat fraction in lower
limb skeletal muscle groups. Results: At 6 years, all 14 muscle groups assessed
demonstrated significant increases in fat fraction, compared to eight groups in
the 1-year follow-up study. In direct contrast to the 1-year follow-up, the 6-
min walk test, 10-m walk or run, timed up and go, stair ascend, stair descend
and chair rise demonstrated significant decline. Among the functional tests,
only FVC significantly declined over both the 1- and 6-year studies. Interpreta-
tion: These results further support fat fraction measurements as a primary out-
come measure alongside functional assessments. The most appropriate
individual muscles are the vastus lateralis, gracilis, sartorius, and gastrocnemii.
Using composite groups of lower leg muscles, thigh muscles, or triceps surae,
yielded high standardized response means (SRMs). Over 6 years, quantitative
fat fraction assessment demonstrated higher SRM values than seen in functional
tests suggesting greater responsiveness to disease progression.
Introduction
Limb girdle muscular dystrophy type R9 (LGMD R9) is
an autosomal recessive disease caused by mutations in the
Fukutin-related protein gene (FKRP).1 LGMD R9 is one of
the most common limb girdle muscular dystrophies in
Northern and Central Europe, with a prevalence of 1 in
230,0002 in the UK and 1 in 54,000 in Norway.3 Most
patients with LGMD R9 share a common homozygous
founder mutation (c.826C>A, p.Leu276Ile) and a rela-
tively mild phenotype compared to the compound
heterozygous form.4,5 LGMD R9 presents with slowly
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progressive muscular weakness, variably affecting skeletal,
respiratory and cardiac muscles.6,7 Onset and severity of
symptoms are highly heterogeneous. Putative therapeutic
approaches, including gene therapy,8,9 immunomodula-
tion10,11 and targeting glycosylation of a-dystroglycan,12
are currently being evaluated. As therapeutics are devel-
oped, it is important to establish sensitive outcome mea-
sures for clinical trials. The most commonly used
outcome measures in clinical trials of muscular dystro-
phies are functional assessments.13 Functional tests are
clinically relevant and are considered important by regula-
tory agencies in therapeutic trial design for muscular dys-
trophies.5 Due to the slow progression of LGMD R9,
standard strength and functional measures of skeletal
muscle were unable to show a significant difference over
1 year.14 Willis et al. investigated the use of the 3-point
Dixon magnetic resonance imaging (MRI) technique,
which allows to calculate fat fraction using acquisitions
with separated water and fat images.15 The percentage of
fat replacement can be used as a biomarker of disease
progression within the LGMD R9 cohort. The study
found that 9/14 muscles of the legs demonstrated a signif-
icant increase in fat replacement over 12 months; the
Dixon technique was more sensitive to disease progres-
sion than functional assessments.14,16
The purpose of this study was to investigate various
outcome measures in the previously recruited LGMD R9
cohort over 6 years. Fat fraction in skeletal muscle and
functional assessments were evaluated to learn more
about the natural history of the disease, to assess the pro-
gression of selective muscle pathology, to identify useful
functional and imaging outcome measures and to inform
future trial design.
Methods
All available participants from the original study, running
from 2009 to 2011,14 were approached to undergo further
functional assessments and quantitative MRI measure-
ments as close to 6 years after the original measurements
as possible. In the original study, the initial recruitment
was from four sites (Newcastle upon Tyne, UK; London,
UK; Copenhagen, Denmark; and Paris, France). The
inclusion and exclusion criteria of the original study
included: homozygous for the c.286C>A, p. L276I muta-
tion, ambulant without support for greater than 50 m, no
ventilator requirement, ability to lie supine, and no con-
traindications to MRI.
As the study by Willis et al. was limited to a 1-year fol-
low up, new ethical approvals were obtained at the four
centers. The study complied with the Declaration of Hel-
sinki and received ethics and R&D approval at all sites
involved.
Participants underwent a series of functional assess-
ments, including: 6-min walk test (6MWT),13,17 10-m
walk or run,18 timed up and go,19 stair ascend, stair des-
cend and chair rise. Myometry was performed on the
dominant side using a hand-held myometer (Citec or
Microfet) assessing: knee flexion, knee extension, hip
abduction, hip adduction, and ankle dorsiflexion. Forced
vital capacity (FVC) was measured and expressed as a
percentage of predicted value for height. Interobserver
consistency was ensured using standardized manuals and
equipment, and training via teleconference. To incorpo-
rate participants unable to perform assessments, results
were expressed as a velocity (msec1 or stairs/sec). For
the 10-m walk or run, the number of meters was divided
by the time taken, the number of stairs (four) was
divided by stair ascend and descend times, and the 6 m
were divided by timed up and go test time. Cardiac func-
tion was monitored as part of clinical care, but this was
not systematically assessed across all centers for the pur-
pose of this study.
Recruitment
At baseline assessment, the median age of the participants
(n = 23) was 39.1 years (interquartile range (IQR) 27.4–
50.6). Median length of follow-up was 6.1 years (IQR
5.8–6.1). In the original study by Willis et al., participants
were required to be ambulant with an ability to walk over
50 m7,14: by 6 years, six participants were nonambulant.
At baseline, no participants received noninvasive ventila-
tion (NIV), by 6 years five participants required NIV
overnight. Seven participants received cardioactive medi-
cation at baseline increasing to thirteen at 6 years.
MRI acquisition
All scans were performed on 3T scanners (Philips Achieva,
Siemens TIM Trio, and Skyra) using surface coil arrays.
Three-point Dixon images were acquired using a spoiled
gradient echo sequence, Newcastle and London used 2D
TR/TE = 100/3.45,4.6,5.75 msec, flip angle of 10 degrees,
10 slices of 10 mm slice thickness with a 5 mm gap. Paris
used a 3D sequence with TR/TE = 10/2.75,3.95,5.15 msec,
flip angle of 3 degrees, 64 slices of 5 mm thickness; Copen-
hagen as per Paris, but with 36 slices per 3D acquisition,
and 2-point Dixon with correction for homogeneity of
B0.
15 The data were processed off-line to produce separate
fat and water images.15,20 Quantitative fat fraction maps
were produced by expressing the fat signal as a percentage
of the total signal per voxel. Phantom measurements and
healthy volunteer images were acquired at each site prior to
the studies. To ensure consistency of positioning among
sites, acquisitions in the legs were positioned with the
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patella anterior and the lower leg images centered by locat-
ing the broadest region of the lower leg and recording the
distance from the lower border of the patella. Positioning
of the thigh images was ensured by locating the superior
border of the patella and acquiring one-third between this
and the anterior superior iliac spine. A matrix of
160 9 160 interpolated to 256 9 256, field of view (FOV)
200 9 200 mm was used with each leg imaged separately.
The Paris site was able to scan both left and right legs at
the same resolution using FOV 448 9 244 mm.
Data analysis
Both functional assessments and MRI data were anon-
ymized and transferred to Newcastle. Regions of interest
(ROIs) were defined using the imaging software ‘Image
J’.21 Two observers drew ROIs independently around the
selected muscle groups at a single level. Data from the left
and right legs were combined by averaging, as were the
results from the two analysts. Interobserver comparison
was performed using a Bland Altman analysis.
The ROIs were used to calculate mean fat fraction and
muscle cross sectional area (CSA). Contractile cross-sec-
tional area (c-CSA) was calculated by multiplying the
CSA by one minus the fat fraction, representing the
remaining muscle content of the ROI.
To reflect the fact that muscles function as groups,
composite group fat fractions were calculated as area-
weighted averages. Composite muscle groups included: all
muscles of the thighs, all muscles of the lower legs,
quadriceps (rectus femoris (RF), vastus lateralis, vastus
medialis), hamstrings (semimembranosus, semitendi-
nosus, biceps femoris short head (BFSH), biceps femoris
long head), and the triceps surae (lateral gastrocnemius,
medial gastrocnemius, soleus).
Following analysis of the fat fraction results, a post
hoc group of potential ‘target muscles’ for use in future
clinical trials was identified. The five muscle groups were
picked to demonstrate progression over 6 years with the
highest standardized response means (SRM ≥0.91) that
had also demonstrated significant change at 1 year in
the Willis study14 (soleus was excluded as it had not
shown significant change at 1 year), allowing interim
analysis. These muscles are reported as an additional
composite group using area-weighted fat fraction averag-
ing in Tables 2 and 3 (“averaged target muscles”). The
averaged target muscle group consisted of the vastus lat-
eralis, gracilis, sartorius, medial gastrocnemius, and lat-
eral gastrocnemius.
In order to identify whether there were particular indi-
viduals who had very low progression of fat replacement
of most muscle groups over the 6 years, we identified for
each participant, how many muscle groups they had that
had a fat fraction of less than 20% fat at baseline and
progressed by less than 20% fat over 6 years.
Statistical analysis
Statistical analysis was performed using SPSS v24, with
data presented as median and range unless otherwise
indicated. Statistical significance was calculated using the
Wilcoxon test for nonparametric data. For nonparametric
testing of the chair rise time, where a participant was
unable to perform a timed functional assessment, a value
greater than the longest possible result (10,000s) was used
to provide correct ranking. Statistical significance was
taken to be P < 0.05.
Standardized response means (SRM) were calculated
for all outcome measures by taking the average of the
paired difference over the 6 years divided by the standard
deviation of these differences. A high SRM (>0.8) implied
that a test had a high level of responsiveness to changes
in value.22
Data availability statement
The anonymized MRI measurements, physical function
tests and clinical characteristics will be made available via
the Dryad data repository (Data available from the Dryad
Digital Repository: https://doi.org/10.5061/dryad.f3r6799).
Results
Functional assessments
All of the timed assessments of skeletal muscle demon-
strated a significant change over 6 years (Table 1). The
6MWT and 10-m walk or run tests had significant change
with P ≤ 0.001 and high SRMs over 6 years (0.85 and 1.02
respectively). Of the myometry assessments, only mea-
surement of hip adduction decreased significantly over
the period of follow-up (median baseline 6.1 kg, median
6 years 4.2 kg, P = 0.02). The annual median FVC
decline in a sitting position was 2.6% (5 to 1.8%),
with 1.9% (7.3 to 1.5%) median annual decline when
in the supine position. Both measures of FVC also had
high SRM (1.29 and 1.06 respectively).
Two participants improved their speed for the 10-m
walk or run assessment over 6 years, however, both
reduced in their 6MWT distance. Over 6 years, the
6MWT distance significantly declined, with six partici-
pants becoming nonambulant. Four participants
improved their distance (mean increase 68.8 m  50.3).
These four subjects showed a fat fraction increase of at
least 1% in the majority of the twenty muscle groups and
composite groups studied (15/20 groups for one patient,
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19/20 groups for two patients and all groups for one
patient). Looking at the increase in fat fraction of the two
participants that improved in 10-m walk or run test
velocity, one had >1% increase in all muscles, the other
had only one muscle with >1% increase.
Quantitative fat fraction
Interobserver consistency of ROI analysis was assessed
using the Bland-Altman analysis. The observers had a
mean difference in fat fraction of 0.05%. The 95% limits
of interobserver agreement ranged from the BFSH at
10.46% down to the soleus at 1.12% (Table S1). The wide
limits of agreement for BFSH are likely due to the small
size of the muscle in the transverse plane. One of the next
widest limits of agreement was found in the RF muscle,
where difficulties defining the borders were complicated
by the high level of fat replacement (Fig. 1). The values
of the RF muscle from two participants were excluded
from analysis due to the high levels of discrepancy
between observers in ROI placement. The interobserver
variability in fat fraction demonstrated in the BFLH,
semitendinosus and semimembranosus muscles may be
caused by high levels of fat replacement at follow-up,
making recognition of ROI borders difficult.
Over the 6 years, all 14 muscle groups demonstrated a
significant increase in percentage of fat replacement
(Table 2 and Fig. 2). The highest median percentage of
fat replacement at baseline was in the biceps femoris long
head muscle (BFLH) at 69.4%, increasing to 78.6% at
6 years. The tibialis anterior muscle (TA) was least
affected at baseline, median 5.2%, and at follow-up
showed a median of 7.1%. The TA also had the smallest
median change over the 6-year period (Fig. 2). LGMD R9
demonstrated phenotypic variability between individuals:
changes in selected functional assessments over time are
shown for individuals in Figure 3. The source data for
these and all other measures are available in the Dryad
data repository. When considering the most complete
composite muscle groups with the highest SRM, there
were small numbers of participants whose fat fraction did
not increase over the 6 years (Fig. 4).
The CSA and c-CSA results are presented in Table 3.
The CSA did not significantly decline in any of the
muscles over the period of the study. The c-CSA was
significantly decreased in 8 of the 14 individual muscles
and in all of the averaged muscle groupings (Table 3).
The median increase in fat fraction per year from this
study and the 12-month Willis study13 is given in
Table S2, together with a correlation between the fat
fraction change over 12 months and 6 years: correlation
indicates where the short-term measurement may be
predictive of long-term change. Significant correlation
was found for the semitendinosus, medial gastrocnemius,
peroneus longus, soleus, vastus medialis, and tibialis
anterior.
Table 1. The median change in functional assessments over the follow-up of 6 years.
Functional assessment
Median baseline
(range)
Median 6 years
(range) P value SRM
Forced vital capacity sitting (%)c 77 (55–94) 64 (31–86) 0.001a 1.29
Forced vital capacity lying (%)d 70 (36–90) 54 (21–84) 0.002a 1.06
Hip flexion (kg) 7.7 (0.0–36.8) 6.4 (0.0–24.3) 0.13 0.35
Hip adduction (kg) 6.1 (0.7–26.7) 4.2 (0–23.9) 0.02a 0.59
Hip abduction (kg) 8.3 (0.6–25.0) 7.2 (2.2–25.3) 0.76 0.01
Knee extension (kg) 11.1 (2.0–40.3) 12.0 (1.5–39.1) 0.15 0.26
Knee flexion (kg) 8.4 (0.9–30.0) 4.8 (0–37.9) 0.21 0.12
Ankle dorsiflexion (kg) 14.7 (2.5–38.6) 13.9 (2.4–26.3) 0.07 0.42
Six-minute walk (meters) 391 (67–625) 286 (0–750) 0.001a 0.85
Timed up and go velocity (msec1)e 0.5 (0.0–1.7) 0.3 (0.0–1.6) 0.007a 0.48
Ten-meter walk or run velocity (msec1)e 1.2 (0.5–4.4) 0.8 (0.0–3.9) <0.001a 1.02
Stair ascent velocity (steps/sec)e 0.7 (0.0–4.4) 0.4 (0.0–3.0) 0.001a 0.46
Stair descent velocity (steps/sec)e 1.2 (0.0–4.4) 0.4 (0.0–3.3) 0.008a 0.47
Chair rise (sec)bc 2.6 (0.3 to ∞) 9.8 (0.5 to ∞) 0.001a N/A
P values calculated using Wilcoxon nonparametric rank signed test. SRM – standardized response mean.
aP value <0.05.
bParticipants unable to perform the chair rise were given a value of 10,000 (effectively infinity) for the purposes of the Wilcoxon nonparametric
rank signed test.
cPaired values available in 17 participants.
dPaired values available in 16 participants.
ePaired values available in 22 participants.
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The 10-m walk or run test velocity and the 6MWT had
several significant negative correlations with the fat frac-
tion of most muscle groups at baseline and 6 years
(Tables S3 and S4. These were strongest in the composite
muscle groups (such as the thigh (r from 0.83 to 0.91,
P < 0.001), hamstrings (r from 0.71 to 0.81, P <
0.001), and quadriceps (r from 0.76 to 0.86,
P < 0.001)) (Tables S3 and S4). Changes in fat fraction
and the 6MWT across 6 years correlated moderately in
the soleus (r = 0.6, P < 0.05), RF (r = 0.53, P < 0.05)
and weakly in some of the composite muscle groups: the
thigh (r = 0.47, P < 0.05), quadriceps (r = 0.46,
P < 0.05), and triceps surae (r = 0.45, P < 0.05).
Changes in fat fraction and the 10-m walk or run test
velocity across 6 years correlated weakly only in the soleus
muscle (r = 0.52, P < 0.05).
Five individuals had less than 20% fat replacement at
baseline, and then progressed by less than 20% over
6 years in all muscle groups. For one further individual,
this was true for eleven muscle groups (Table 4). This
group of six subjects whom we termed “slow progres-
sors”, were significantly younger than the other 17 par-
ticipants (median age at baseline 23.5 vs. 43.0 years,
P < 0.001).
To provide a sense of the heterogeneity in fat fraction
changes between individual subjects, we provide Table 4
Figure 1. Box plot showing the change in fat percentage from baseline to 6 years. The blue bars show the interquartile range and the median.
The lines show the range of the data. Outliers one to three times the interquartile range are marked as circles. Outliers greater than three times
the interquartile range from the median are shown as individual asterisks. The median change is shown for each muscle group on the left. Note
that the median change will not be equal to the difference in the median baseline and 6 year medians given in Table 2. a Due to difficulties in
ROI placement in the rectus femoris muscle, the fat fractions for two participants were excluded for this muscle group, and no composite results
calculated where appropriate (n=21).
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which includes individual details of clinical characteristics,
baseline values for the 6MWT and 10-min walk or run, and
baseline and 6-year changes in fat fraction for the target
and triceps surae muscle groups. These muscle groups were
chosen since they are available for all subjects and had high
SRMs at 6 years. There is also information on whether
these subjects lost ambulation at 6 years and/or were
unable to perform the chair rise. The participants are
ordered in decreasing order of fat fraction increase in the
target muscles across 6 years (changes ranged from 36.2%
to 0.0%). Similar individual results for other muscle groups
can be obtained within the Dryad data repository.
Discussion
As putative therapies for LGMD R9 are evaluated,8,10,12 sen-
sitive longitudinal outcome measures are required.5 This
study built upon our previous 1-year study,14 representing
the longest and largest multicenter study of LGMD R9 to
date. These results provide support for 3-point Dixon tech-
nique as an outcome measure over both 1 and 6 years and
identified functional assessments significantly declining over
a 6-year period, whereas significant decline could not be
detected in functional assessments over 1 year.14
Functional assessments
A recent workshop assessing trial readiness in LGMD R9
highlighted the need for MRI alongside other functional
assessments, with emphasis on measuring movements that
affected quality of life.5 The results of this study and Wil-
lis et al. suggested that the Dixon technique can reliably
detect changes in leg muscles over 1 and 6 years in
LGMD R9. None of the ambulatory skeletal muscle func-
tional assessments demonstrated a significant difference
over 1 year.14 Our study suggests that, over 6 years, all
timed muscle function tests demonstrated disease progres-
sion, though of the hand-held myometry tests, only hip
adduction strength was significantly decreased. The
6MWT and 10-m walk or run tests had high SRMs over
6 years; these assessments are therefore worth measuring
over the longer time period, even though insensitive over
12 months. There was a degree of individual variability in
functional assessments at 6 years with two participants
increasing their velocity on the 10-m walk or run but
reducing their 6MWT distance. The differences between
the fat fraction increase and the results of the 6MWT and
10-m walk or run test support MRI as a more meaningful
outcome measure and highlight the participant-dependent
Table 2. Median muscle fat fractions at baseline and 6-year follow up.
Muscle group Median baseline (range), % Median 6 years (range), % P value SRM
Rectus femorisbc 10.8 (0.9–81.9) 19.9 (0.4–92.2) <0.001a 0.90
Vastus medialis 21.0 (1.1–86.6) 44.4 (2.5–87.9) <0.001a 0.83
Vastus lateralisc 13.7 (1.5–65.2) 36.1 (2.8–81.7) <0.001a 0.92
Sartoriusc 20.9 (1.7–89.8) 34.2 (5.4–88.3) <0.001a 0.98
Gracilisc 18.4 (3.7–81.0) 32.4 (4.5–90.2) <0.001a 1.04
Biceps femoris long headc 69.4 (2.2–97.7) 78.6 (4.8–100) 0.001a 0.81
Biceps femoris short head 21.3 (3.2–94.5) 32.5 (4.6–84.3) 0.002a 0.53
Semitendinosusc 35.6 (2.1–100) 69.6 (4.1–100) <0.001a 0.83
Semimembranosusc 25.7 (0.5–95.1) 53.4 (4.6–99.2) <0.001a 0.90
Tibialis anterior 5.2 (0.9–25.3) 7.1 (1.1–27.1) 0.002a 0.67
Peroneus longus 15.8 (3.0–46.2) 18.0 (4.6–65.2) 0.001a 0.88
Soleus 7.5 (1.8–67.4) 16.7 (3.1–70.1) <0.001a 1.17
Lateral gastrocnemiusc 19.4 (0.9–76.1) 35.8 (3.1–75.2) <0.001a 0.91
Medial gastrocnemiusc 19.9 (1.1–91.8) 48.0 (2.8–84.2) <0.001a 0.95
Averaged thighb 30.8 (2.1–76.2) 47.3 (4.2–82.1) <0.001a 1.20
Averaged lower leg 15.4 (1.6–56.1) 26.8 (3.4–55.5) <0.001a 1.28
Averaged quadricepsb 23.0 (1.3–67.6) 40.4 (2.6–79.8) <0.001a 1.05
Averaged hamstrings 45.0 (2.8–97.8) 60.4 (4.7–98.7) <0.001a 0.93
Averaged triceps surae 16.7 (1.4–74.2) 30.3 (3.3–72.6) <0.001a 1.25
Averaged target muscles 21.5 (1.8–70.8) 43.8 (3.6–76.9) <0.001a 1.23
P values calculated using Wilcoxon nonparametric rank signed test. SRM – standardized response mean.
aP value<0.05.
bDue to difficulties in ROI placement in the rectus femoris muscle the fat fractions for two of the participants were excluded for this muscle group
(n = 21). As the rectus femoris measures are excluded from two participants, it is not possible to create composite measures (thigh and quadri-
ceps) involving this muscle for these participants. The thigh and quadriceps measures are based on 21 participants.
cExhibited a significant increase in fat fraction over a 1-year period taken from Willis et al.7
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factors of functional testing (such as effort or fatigue). In
contrast to Duchenne muscular dystrophy (DMD) stud-
ies,23 there was no clear cut-off in distance walked at
baseline which could predict nonambulation in the
LGMD R9 cohort at 6 years.
The only myometry measurement which demonstrated
a significant decline over 6 years was hip adduction. This
suggests limited sensitivity to change in a slowly progress-
ing disease. All timed functional assessments demonstrated
a significant decline, with only the 6MWT and the 10-m
Figure 2. Images showing the change in fat replacement over 6 years. Fat fraction maps acquired from the left thigh and lower leg at baseline
and 6-year follow-up (0–100% scale). Progression of fat replacement was visible in almost all muscles, with changes most noticeable in the
muscles relatively spared at baseline, such as the Sartorius (white arrow A - in this participant fat fraction increased from 21.3% to 34.2%) and
the gracilis (white arrow B - increased from 40.3% to 58.7%) muscles. As indicated by the white arrow (C), fat replacement began at the
borders of the rectus femoris muscle at both baseline and 6 years, which caused difficulties in ROI placement. In this participant, the fat fraction
was 78.9% at baseline increasing to 81.9% at 6 years. The shape and size of the biceps femoris short head muscle also caused difficulties in ROI
placement as demonstrated by the white arrow (D).
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walk or run velocity having SRM values >0.5 (Table 1).
In DMD, myometry measurements may be predictive of
decline, though they are not always significant even over
2 years.23 The timed tests lack the sensitivity to detect
the slowly progressive weakness of LGMD R9 over
1 year.14
FVC was the only functional assessment which changed
significantly in 1 year and over a 6-year period
(Table 1).14 The median annual decline is less than
reported elsewhere, perhaps explained by the wide age-
range of our cohort.14,24 Respiratory muscle involvement
is only indirectly linked to ambulatory skeletal muscle
involvement. The rate of annual median FVC decline was
not clinically significant but likely to have a cumulative
effect.
As a potential clinical trial outcome measure, the 6MWT
and 10-m walk or run were the only functional timed
assessments relating to skeletal muscle demonstrating a sig-
nificant difference over 6 years with all participants
included at baseline. The 6MWT, 10-m walk or run, timed
up and go, chair rise, stair ascend, and stair descend tests
are important to include as outcome measures in future
trials investigating LGMD R9 cohorts. Our study demon-
strated that quantitative MRI was more sensitive within
this cohort, most likely due to the slow progression of the
LGMD R9 phenotype.
Figure 3. Line graphs demonstrating individual participant progression in functional tests from baseline to 6 years. The functional assessments
with the highest SRM values were selected to compare individual progression over time. On the 6-min walk test, there was no clear cut-off for
predicting loss of ambulation, 6/9 participants who walked ≤300 m became nonambulant by 6 years. Two participants improved on both the 10-
m walk or run test and sitting forced vital capacity.
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Fat replacement as an outcome measure
The fat fraction has been established as a sensitive measure
of disease progression in muscular dystrophies.14,25–33 The
fat fraction of all 14 muscles assessed significantly
increased over 6 years.
For every muscle group, the SRM for the c-CSA is of
smaller magnitude (and the P value less significant) than
for the respective fat fraction alone, indicating that the
variability in the cross-sectional areas within the group
outweighs the small yet progressive changes in fat frac-
tion. LGMD R9 has been associated with a lower c-CSA
compared to controls, but preserving the ratio between
the c-CSA and torque34: it is not possible to confirm this
relationship in the present data due to different physical
function tests used. c-CSA has been shown to correlate to
functional measures of strength in other muscular dystro-
phies.34,35 In this case, c-CSA is a less sensitive endpoint
than fat fraction alone.
To maximize the discriminant power of quantitative
MRI as a biomarker for therapeutic studies, it was useful
to select muscle groups for analysis. Variability of muscle
involvement and ability to demonstrate a significant
change over short intervention periods are important.
Willis et al. identified nine muscle groups whose fat frac-
tions increased significantly over a 12-month period.14 In
the upper leg, the vastus lateralis, sartorius and gracilis
muscles were easily identifiable at baseline and follow-up.
In the lower leg, Willis et al. suggested that the medial
gastrocnemius muscle should be used for analysis.14 Both
Figure 4. Line graphs demonstrating individual participant progression in fat fraction from baseline to 6 years. The composite muscle measures
with the highest SRMs were selected to compare individual progression over time. Quadriceps and thigh measures were excluded as these were
not available in all participants due to difficulties in ROI placement in the rectus femoris. The individual lines suggest there is only one participant
who does not progress over the 6 years and six participants who have little infiltration at baseline and increase relatively slowly over the 6 years.
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at baseline and 6 years, the medial and lateral gastrocne-
mii muscles had similar levels of fat fraction with little
difference in variability (Table 2). The results showed sev-
eral highly significant p values coupled with high SRM
values, suggesting that to maximize power in a trial the
following muscles should be targeted in the thigh: vastus
lateralis, gracilis, and sartorius. In the calves, both of the
gastrocnemii muscles should be included for analysis.
Other thigh muscles, including the BFLH, semitendinosus
and semimembranosus, would not be suitable in spite of
high SRM values. These muscles showed high fat fractions
at baseline, making it likely that therapeutic response
would be small. High levels of fat at baseline also
increased the difficulty and reliability of ROI placement.
Fat fractions of the vastus medialis, BFSH and remaining
calf muscles (peroneus longus, soleus, and TA) were less
suitable endpoints due to lack of significant differences at
1 year in the Willis study,14 reducing the usefulness of
any interim analysis. Other composite muscle groups such
as the averaged thigh, averaged lower leg and averaged
triceps surae muscles had high SRM values, similar to the
value of the target muscle group. Therefore, these com-
posite measures may have utility as a powerful outcome
measure.
Looking at the characteristics of the individual subjects
using the target muscle and triceps surae groups as exemplars
(Table 4), those at the bottom of the table with least change in
fat fraction tended to have the lowest baseline fat fractions,
though there were exceptions. Likewise, there was no particu-
lar value of baseline 6MWT or 10-m walk or run that pre-
dicted greater change in this group.
It is important to acknowledge that these results may
underestimate progression of the disease process with
most severely affected individuals less likely to return at
6 years due to difficulties in travelling. Other limitations
included that only one slice was analyzed in each subject
at a predefined level whereas multislice analysis could take
account of heterogeneity in disease progression. While
there were many possible correlations between fat fraction
calculations and functional measures, this work concen-
trated principally on the sensitivity of outcome measures
to detect change over time. For future work, it would be
appropriate to accompany MRI and functional testing
with self-reported Quality of Life assessment tools as per
recent recommendations5: several suitable options exist
including the Quality of Life in genetic Neuromuscular
Disease questionnaire (QoL-gNMD),36 the Activity Limi-
tation (ACTIVLIM) questionnaire for neuromuscular dis-
orders37 and general tools such as the Fatigue Severity
Scale.38
This study is the longest follow-up of a LGMD R9 cohort
and demonstrated that fat fraction measurement was the
Table 3. Median cross-sectional area (CSA) and contractile cross-sectional area (c-CSA) at baseline and 6 years.
Muscle group CSA baseline (mm2) CSA 6 years (mm2) c-CSA baseline (mm2) c-CSA 6 years (mm2) P value c-CSA SRM
Rectus femorisb 343 344 260 232 0.009a 0.51
Vastus medialis 720 932 428 389 0.11 0.15
Vastus lateralis 1639 1517 1195 1025 0.003a 0.62
Sartorius 402 425 346 231 0.06 0.41
Gracilis 344 309 168 154 0.003a 0.64
Biceps femoris long head 1012 911 316 145 0.02a 0.49
Biceps femoris short head 153 157 110 81 0.63 0.16
Semitendinosus 687 679 316 206 0.002a 0.71
Semimembranosus 685 671 410 301 0.04a 0.37
Tibialis anterior 568 569 536 537 0.67 0.20
Peroneus longus 578 546 464 436 0.09 0.29
Soleus 1803 1635 1512 1430 0.09 0.35
Lateral gastrocnemius 553 523 435 317 0.04a 0.39
Medial gastrocnemius 1243 993 879 516 0.02a 0.53
Averaged thighb 6024 6071 3288 3087 0.006a 0.55
Averaged lower leg 4263 4264 3637 3365 0.01a 0.52
Averaged quadricepsb 3078 3103 2017 1577 0.01a 0.44
Averaged hamstrings 2322 2347 1101 842 0.007a 0.63
Averaged triceps surae 3272 3113 2834 2469 0.009a 0.53
Averaged targeted muscles 4211 3803 2745 2248 0.005a 0.67
All P values quoted refer to c-CSA. There are no significant changes in CSA between baseline and 6 years.
SRM, standardized response mean.
aDenotes a P value <0.05.
bDue to difficulties in ROI placement in the rectus femoris muscle, the fat fractions for two of the participants were excluded for this muscle
group (n = 21).
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most sensitive marker of disease progression over a 6-year
period. Long-term natural history data are of value in post-
marketing and long-term surveillance in these rare diseases.
Use of the Dixon technique can provide useful interim mea-
sures of disease progression not currently possible with
functional testing, and can be deployed in patients unable to
complete all functional tests. Our results support fat fraction
measurement in LGMD R9 clinical trials as a primary out-
come measure alongside functional assessments: The
6MWT and the 10-m walk or run were the most appropri-
ate, relevant functional measures for a longer therapeutic
trial. This study provides direction for clinical trial develop-
ment and outcome measures for powering future random-
ized controlled trials into LGMDR9.
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eSlow progressor, defined as: the majority of muscle groups with <20% FF baseline and <20% increase over 6 years.
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